Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Viatris’s stock price has taken a beating over the past six months, shedding 33% of its value and falling to $7.69 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer.
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary, hematologic, and thoracic cancers, as well as colorectal cancer.
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients.
Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street.
